These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32534701)

  • 1. miR-194-5p inhibits SLC40A1 expression to induce cisplatin resistance in ovarian cancer.
    Wu J; Zhang L; Wu S; Yi X; Liu Z
    Pathol Res Pract; 2020 Jul; 216(7):152979. PubMed ID: 32534701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3β/β-catenin signaling pathway.
    Dai J; Wei R; Zhang P; Kong B
    J Transl Med; 2019 Jun; 17(1):190. PubMed ID: 31171023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
    Ge T; Liu T; Guo L; Chen Z; Lou G
    Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
    Wu D; Lu P; Mi X; Miao J
    Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
    Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
    Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Feedback Loop Between miR-30a/c-5p and DNMT1 Mediates Cisplatin Resistance in Ovarian Cancer Cells.
    Han X; Zhen S; Ye Z; Lu J; Wang L; Li P; Li J; Zheng X; Li H; Chen W; Li X; Zhao L
    Cell Physiol Biochem; 2017; 41(3):973-986. PubMed ID: 28222434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
    Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
    Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2.
    Zhao H; Yu X; Ding Y; Zhao J; Wang G; Wu X; Jiang J; Peng C; Guo GZ; Cui S
    Oncotarget; 2016 Aug; 7(33):53254-53268. PubMed ID: 27449101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
    Lin M; Xia B; Qin L; Chen H; Lou G
    DNA Cell Biol; 2018 May; 37(5):491-500. PubMed ID: 29485916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes.
    Li X; Chen W; Jin Y; Xue R; Su J; Mu Z; Li J; Jiang S
    Biochem Pharmacol; 2019 Mar; 161():98-112. PubMed ID: 30639456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nrf2 induced cisplatin resistance in ovarian cancer by promoting CD99 expression.
    Wu J; Zhang L; Li H; Wu S; Liu Z
    Biochem Biophys Res Commun; 2019 Oct; 518(4):698-705. PubMed ID: 31472965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-335-5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2.
    Liu R; Guo H; Lu S
    Cancer Med; 2018 Sep; 7(9):4598-4609. PubMed ID: 30019389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-590-5p promotes cisplatin resistance via targeting hMSH2 in ovarian cancer.
    Li B; Xu X; Zheng L; Jiang X; Lin J; Zhang G
    Mol Biol Rep; 2023 Aug; 50(8):6819-6827. PubMed ID: 37392283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
    Xiao F; Li Y; Wan Y; Xue M
    Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knockdown of long non-coding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated EZH2 and SIRT1.
    Zhang Y; Ai H; Fan X; Chen S; Wang Y; Liu L
    Biol Res; 2020 Apr; 53(1):18. PubMed ID: 32349783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer.
    Chen Y; Cao XY; Li YN; Qiu YY; Li YN; Li W; Wang H
    Am J Physiol Cell Physiol; 2018 Aug; 315(2):C225-C235. PubMed ID: 29719173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer.
    Liu MX; Siu MK; Liu SS; Yam JW; Ngan HY; Chan DW
    Oncotarget; 2014 Feb; 5(4):944-58. PubMed ID: 24659709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. G-5555 synergized miR-485-5p to alleviate cisplatin resistance in ovarian cancer cells via Pi3k/Akt signaling pathway.
    Qiao HF; Liu YL; You J; Zheng YL; Chen LP; Lu XY; Du L; Shan F; Liu MH
    J Reprod Immunol; 2020 Aug; 140():103129. PubMed ID: 32334286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-219-5p attenuates cisplatin resistance of ovarian cancer by inactivating Wnt/β-catenin signaling and autophagy via targeting HMGA2.
    Song Z; Liao C; Yao L; Xu X; Shen X; Tian S; Wang S; Xing F
    Cancer Gene Ther; 2023 Apr; 30(4):596-607. PubMed ID: 36494581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ΜiR-182-5p functions as a tumor suppressor to sensitize human ovarian cancer cells to cisplatin through direct targeting the cyclin dependent kinase 6 (CDK6).
    Duan L; Yan Y; Wang G; Xing YL; Sun J; Wang LL
    J BUON; 2020; 25(5):2279-2286. PubMed ID: 33277846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.